Basket trials in oncology: A trade-off between complexity and efficiency

Journal of Clinical Oncology

Volumn 35, Issue 3, 2017, Pages 271-273

  Cunanan, Kristen M ^a   Gonen, Mithat ^a   Shen, Ronglai ^a   Hyman, David M ^a   Riely, Gregory J ^a   Begg, Colin B ^a   Iasonos, Alexia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CRIZOTINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; NEW DRUG;

CANCER LOCALIZATION; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; METASTATIC MELANOMA; NOTE; ONCOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STATISTICAL ANALYSIS; STUDY DESIGN; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; FEMALE; MALE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES; SENSITIVITY AND SPECIFICITY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; FEMALE; HUMANS; MALE; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN; SENSITIVITY AND SPECIFICITY; VEMURAFENIB;

EID: 85010046656     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.9751     Document Type: Note

References (15)

1. Redig AJ, Jänne PA: Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 33:975-977, 2015
2. Hyman DM, Puzanov I, Subbiah V, et al: Vemurafenib in multiple non-melanoma cancers with BRAF V600 mutations. N Engl J Med 373:726-736, 2015
3. European Organisation for Research and Treatment of Cancer: Trial # 90101 ("CREATE"): Cross-tumoral phase 2 clinical trial exploring Crizotinib in patients with advanced tumors induced by causal alteration of ALK and/or MET. http://www.eortc.org/sites/default/files/90101.pdf
4. Lopez-Chavez A, Thomas A, Rajan A, et al: Molecular profiling and targeted therapy for advanced thoracic malignancies: A biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol 33:1000-1007, 2015
5. Conley BA, Doroshow JH: Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 41:297-299, 2014
6. Burris HA, Hurwitz H, Perez EA, et al: MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents. ASCO Poster Session, 2015. http://meetinglibrary.asco.org/print/2005451
7. Kang BP, Slosberg E, Snodgrass S, et al: The signature program: Bringing the protocol to the patient. Clin Pharmacol Ther 98:124-126, 2015
8. ASCO: Targeted Agent and Profiling Utilization Registry Study. http://www.tapur.org
9. Mandrekar SJ, Dahlberg SE, Simon R: Improving clinical trial efficiency: Thinking outside the box. Am Soc Clin Oncol Educ Book e141-e147, 2015
10. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
11. Drilon A, De Braud FG, Siena S, et al: Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results. http://goo.gl/9BbloV
12. Cunanan K, Iasonos A, Shen R, et al: An efficient basket trial design. http://biostats.bepress.com/mskccbiostat/paper31/
13. Leblanc M, Rankin C, Crowley J: Multiple histology phase II trials. Clin Cancer Res 15:4256-4262, 2009
14. Berry SM, Broglio KR, Groshen S, et al: Bayesian hierarchical modeling of patient subpopulations: Efficient designs of phase II oncology clinical trials. Clin Trials 10:720-734, 2013
15. Simon R, Geyer S, Subramanian J, et al: The Bayesian basket design for genomic variant-driven phase II trials. Semin Oncol 43:13-18, 2016